Compare BBAR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | ZLAB |
|---|---|---|
| Founded | 1886 | 2013 |
| Country | Argentina | China |
| Employees | 6493 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 1997 | 2017 |
| Metric | BBAR | ZLAB |
|---|---|---|
| Price | $14.55 | $25.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $49.60 |
| AVG Volume (30 Days) | 832.9K | ★ 923.4K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $18.32 | $9.75 |
| Revenue Next Year | $11.04 | $26.03 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $7.76 | $15.96 |
| 52 Week High | $22.47 | $34.72 |
| Indicator | BBAR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.50 | 51.52 |
| Support Level | $13.43 | $16.84 |
| Resistance Level | $15.68 | $25.28 |
| Average True Range (ATR) | 0.71 | 0.79 |
| MACD | 0.12 | -0.42 |
| Stochastic Oscillator | 26.32 | 30.05 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.